FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

11 letters match. Newest first.

  1. Lovelace Biomedical Research Institute

    Lovelace Biomedical's quality unit failed to ensure final drug study reports matched raw data, FDA says.

    Medium
  2. HealthPartners Neuroscience Center Research and Innovation

    FDA warned HealthPartners Neuroscience Center that its animal studies of an investigational drug violated good laboratory practice rules.

    Medium
  3. Vedic Lifesciences Pvt. Ltd.

    FDA warns Vedic Lifesciences over false final reports for three nonclinical drug studies.

    Medium
  4. Palamur Biosciences Private Limited

    FDA warns Palamur Biosciences over GLP violations in medical device safety testing and inadequate corrective actions.

    High risk
  5. Jiangsu Kerbio Medical Technology Group Co.

    FDA cites Jiangsu Kerbio Medical Technology Group for serious GLP violations in medical device safety testing.

    High risk
  6. CCIC Huatongwei International Inspection Co., Ltd.

    FDA warns CCIC Huatongwei after inspection found copied data and missing records in medical device safety tests.

    High risk
  7. Mid-Link Testing Company, Ltd

    FDA warns Mid-Link Testing over unreliable Good Laboratory Practice (GLP) safety data for medical device tests.

    High risk
  8. Sanitation & Environmental Technology Institute dba SDWH

    FDA found GLP violations in SDWH's nonclinical testing of medical devices, raising doubts about safety data.

    High risk
  9. Samm Solutions, Inc., d.b.a. BTS Research

    Samm Solutions/BTS Research failed good laboratory practice (GLP) rules for nonclinical drug studies, FDA says.

    Medium
  10. Valley Biosystems

    FDA cited Valley Biosystems, a California biologics testing lab, for Good Laboratory Practice violations that call its nonclinical study data into question.

    High risk
  11. Toxikon Corporation/Labcorp Bedford LLC

    FDA warned Toxikon/Labcorp Bedford over GLP violations in a biologics nonclinical study, including incorrect kidney-function calculations and failed QA review.

    Medium